Company Overview and News
OGE Energy Corp’s. (OGE - Free Report) subsidiary, Oklahoma Gas & Electric Company (OG&E), recently signed an agreement with Oklahoma Corporation Commission (OCC) and other regulatory parties to review rates for its Oklahoma customers. If approved, the new rates will take effect from Jul 1, 2018. Alongside the agreement, the company also reaffirmed its 2018 earnings guidance. It continues to expect the net income in the range of $380-$410 million or $1.
DUKH AGR DUK SPG NEE OGE
Duke Energy Corp.’s (DUK - Free Report) subsidiary, Piedmont Natural Gas, recently announced that it has received the regulatory nod for altering its natural gas rates from the North Carolina Utilities Commission (NCUC). As a result, the average residential customer of Duke Energy in North Carolina will witness a $1 decline in their monthly bill. The changes will be effective from Jun 1, 2018.
DUKH WGL AGR DUK NEE
(Reuters) - Massachusetts on Wednesday selected a partnership between Avangrid Inc and Copenhagen Infrastructure Partners to develop what will be the largest U.S. offshore wind farm off the coast of Martha’s Vineyard.
ES NG NGGTF AGR NGG
2018-05-03 sec.gov - 1
agr-10q_20180331.htm UNITED STATES SE
* AVANGRID INC - ON APRIL 25, BOARD APPOINTED DOUGLAS STUVER AS SENIOR VICE PRESIDENT - CHIEF FINANCIAL OFFICER Source text: (bit.ly/2HIsqt6) Further company coverage:
Xcel Energy Inc. (XEL - Free Report) recorded first-quarter 2018 operating earnings of 57 cents per share, beating the Zacks Consensus Estimate of 51 cents by 11.8%. Also, the bottom line was 21.3% lower than the year-ago quarter. The year-over-year increase in earnings was due to improvement in electric and natural gas margins, thanks to favorable weather compared to last year. GAAP earnings in the quarter were 57 cents compared with 47 cents reported in the year-ago quarter.
XEL YUM SQ SQNXF AGR UTX FE NEE
2018-04-24 247wallst - 3
Stocks had been selling off up until today, but the major equity indices were up after strong earnings from the Dow Jones industrials added support. Some investors have reconsidered what the nine-year bull market may bring in 2018 and beyond. It is clear that the trend of buying pullbacks has become more vulnerable to sellers, volatility and each major news headline. Many investors are finding it hard to decide how they want their assets positioned for the longer term.
EPZM BP NVDA GOOG ACT KEY BP.A BP.B AAI BP AGN GOOGL FDC AGR TRI BPAQF FSLR FE AA
Good day ladies and gentlemen and welcome to the Q1 2018 Avangrid Inc. earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions].
CTGSP POR UIL AGR
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to AGR / Avangrid, Inc. on message board site Silicon Investor.
as of ET